HomeAI · summaries
Storia in 3 fonti
Ollin refuels with $330M to back pivotal tests of Vabysmo challenger
One of the year’s largest venture funding rounds comes just after a head-to-head study showed Ollin’s drug — licensed from a China-based developer — had certain advantages over Roche’s eye treatment.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Ollin refuels with $330M to back pivotal tests of Vabysmo challenger
One of the year’s largest venture funding rounds comes just after a head-to-head study showed Ollin’s drug — licensed from a China-based developer — had certain advantages over…
- ·
statnews.com
Ophthalmology venture grabs investors’ attention, raises $330 million
A startup developing treatments for eye diseases has raised $330 million from investors as it readies for late-stage testing.
